hyaluronic acid and derivatives (Rx)Brand and Other Names:Orthovisc, Synvisc, more...Synvisc-One, Monovisc, hyaluronan, hylan G-F 20

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

intra-articular injection (prefilled syringe)

  • 16mg/2mL (Synvisc)
  • 30mg/2mL (Orthovisc)
  • 48mg/6mL (Synvisc-One)
  • 88mg/4mL (Monovisc)
more...

Osteoarthritis of the Knee

Indicated for treatment of pain in osteoarthritis of the knee

Synvisc: Inject intra-articularly 16 mg (2 mL) to affected knee qWeek for 3 weeks

Synvisc-One: Inject intra-articularly 48 mg (6 mL) to affected knee once as a single injection

Orthovisc: Inject intr-articularly 30 mg (2 mL) to affected knee qWeek for 3 weeks

Monovisc: Inject intra-articularly 88 mg (4 mL) to affected knee once as a single injection

Administration

Concomitant use of disinfectants containing quaternary ammonium salts (eg, benzalkonium chloride) for skin preparation can precipitate in presence of hyaluronic acid

Use strict aseptic injection technique

Inject the full contents of single syringe intra-articularly into 1 knee only; if treatment is bilateral, a separate syringe should be used for each knee

Safety and efficacy not established

Next

Adverse Effects

>10%

Arthralgia (25%)

Tenderness (61-92%)

Swelling (81-91%)

Firmness (88-89%)

Bruising (52-87%)

Pruritus (25-36%)

Skin discoloration (33-78%)

Firmness (86-89%)

Lumps/bumps (56-83%)

1-10%

Increased blood pressure (4%)

Fatigue (1%)

Nausea (<2%)

Injection site pain (3%)

Paresthesia (1%)

Tendonitis (2%)

Limb pain (1%)

Tendonitis (2%)

Joint effusion (2%)

<1%

Angioedema

Arthritis

Herpetic eruptions

Thrombocytopenia

Peripheral edema

Vasovagal reaction

Hives

Gait disturbances

Previous
Next

Warnings

Contraindications

Hypersensitivity to hyaluronate preparations, avian-derived products (eg, eggs, feathers, poultry), gram-positive bacterial proteins

Do not inject in knees with infection or skin diseases in area of injection site or joint

Cautions

Transient increased inflammation in injected knee may occur

Avoid strenuous activity or prolonged (>1 hr) weight-bearing activities (eg, running, tennis) within 48 hr following injection

Pain relief may not be evident until after 3rd injection

Remove joint effusion, if present, before injection

Not for injection intra-articular into synovium

Previous
Next

Pregnancy & Lactation

Pregnancy Category: Not tested in pregnant women

Lactation: Unknown whether distributed in breast milk, caution advised

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next

Pharmacology

Mechanism of Action

When injected intra-arterially, supplements joint cushioning to temporarily provide pain relief caused by osteoarthritis

High molecular weight polysaccharide composed of repeating disaccharide units of sodium glucuronate and N-acetylglucosamine; derived from bacterial cells

Previous
Next

Images

Previous
Next

Formulary

FormularyPatient Discounts

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Add or Remove Plans
Plans for
Select State:
Non-Medicare PlansMedicare Plans

Select a box to add or remove a plan.

Select a class to view formulary status for similar drugs

Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.